

# Appendix 3D

## Changes relating to buy-back (except minimum holding buy-back)

*Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

|                               |                |
|-------------------------------|----------------|
| Name of entity                | ABN/ARSN       |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

|   |   |                  |
|---|---|------------------|
| 1 | Date that an Appendix 3C or the last Appendix 3D was given to ASX | 18 November 2015 |
|---|---|------------------|

### Information about the change

*Complete each item for which there has been a change and items 9 and 10.*

|                           | Column 1<br>(Details announced to market in Appendix 3C or last Appendix 3D)   | Column 2<br>(Details of change to buy-back proposals)   |
|---------------------------|--|---|
| <b>On-market buy-back</b> |  |   |
| 2                         | Name of broker who will act on the company's behalf  | Goldman Sachs Australia Pty Ltd<br>No change  |
| 3                         | Deleted 30/9/2001.   |   |
| 4                         | If the company/trust intends to buy back a maximum number of shares/units – that number<br><br><small>Note: This requires a figure to be included, not a percentage. The reference to a maximum number is to the total number including shares/units already bought back and shares/units remaining to be bought back. If the total has not changed, the item does not need to be completed.</small> | No change to the maximum number of shares as would have been calculated at 13 September 2012<br>No Change |

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3D**  
**Changes relating to buy-back**

---

|   | <b>Column 1</b><br>(Details announced to market in Appendix 3C or last Appendix 3D) | <b>Column 2</b><br>(Details of change to buy-back proposals) |
|---|---|--|
| 5 If the company/trust intends to buy back a maximum number of shares/units – the number remaining to be bought back  | 8,169,101   | 5,280,247  |
| 6 If the company/trust intends to buy-back shares/units within a period of time – that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention | 18 November 2015 to<br>18 November 2016   | 26 November 2016 to<br>26 November 2017                      |
| 7 If the company/trust intends to buy back shares/units if conditions are met – those conditions  | Not applicable  | No change  |

**All buy-backs**

|                     |                          |           |
|---------------------|--------------------------|-----------|
| 8 Any other change  | Not applicable           | No change |
| 9 Reason for change | Buy-back period extended |           |

---

<sup>+</sup> See chapter 19 for defined terms.

- 10 Any other information material to a shareholder's/unitholder's decision whether to accept the offer (*eg, details of any proposed takeover bid*)

Not applicable

## Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here: .....  
(Company Secretary)

Date: 11 November 2016

Print name: Sam Lawson

== == == == ==

---

<sup>+</sup> See chapter 19 for defined terms.